Navigation Links
Oncology is the Most Active Therapeutic Area for Phase II/III R&D
Date:11/21/2013

BURLINGTON, Mass., Nov. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while metabolic drugs account for one-quarter of drugs recently filed for approval or approved, oncology continues to be the most active therapeutic area for Phase II and III research and development (R&D). Among the top 25 biopharmaceutical companies, oncology is the focus for 30 percent of Phase II drugs and 22 percent of Phase III drugs. According to Decision Resources' Strategic Insights report entitled R&D Trends: Will Pharma's Investment Deliver?, other active therapeutic areas of R&D include obesity drugs, anti-diabetics, anti-infectives, central nervous system drugs, musculoskeletal/pain drugs and respiratory drugs.

The analysis also reveals that despite enduring multiple failures in 2011 and 2012 with drugs in Phase III development, Novartis is poised to benefit from a rich Phase III pipeline. Decision Resources expects Novartis will replace Pfizer as the top global biopharmaceutical company in 2015.

"To maximize R&D investments, biopharmaceutical companies must continue to address Phase II and III attrition and identify better prospects early on," said Decision Resources Group Senior Vice President Kate Hohenberg. "As more than half of the costs associated with new drugs are accrued from Phase II on, this could lead to significant cost savings."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company. <
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013s Top Oncology Projects to Watch
2. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
3. In The Face Of Increasing Healthcare Spend And High-Cost Targeted Treatment, Market Access Barriers Continue To Rise For Targeted Oncology Drugs
4. Elekta Opens Global Education Center for Oncology and Neuroscience Professionals
5. Enhanced Strategies for Design and Execution of Biomarker-driven Oncology Trials, new life science webinar hosted by Xtalks
6. Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition
7. Oncology Therapeutics Market in India to 2018 Report
8. Vermillions OVA1 Receives New Statement by Society of Gynecologic Oncology
9. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
10. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
11. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... BETHESDA, Md. , May 6, 2015  Northwest Biotherapeutics ... personalized immune therapies for solid tumor cancers, today announced that ... overview of the Company,s DCVax cancer vaccine platform for solid ... on May 7, 2015.   , ... , , , , TIME: , , , 12:15 ...
(Date:5/6/2015)... May 06, 2015 Park Systems ... NX-Hivac, the only high vacuum AFM system in the ... failure analysis semiconductor manufacturing. Park NX-Hivac is ideal for ... analysis solutions in highly doped semiconductor processing where more ... , The high vacuum scanning spreading resistance microscopy (SSRM) ...
(Date:5/6/2015)... Histogen, Inc., a regenerative medicine company ... grown under simulated embryonic conditions, will present new ... melanoma during the 2015 Society of Investigative Dermatology ... in Atlanta, GA. , Histogen has previously shown ... with anti-oncologic properties, with potential benefit in the ...
(Date:5/6/2015)... The Remedy Group , the premier ... specialty pharmacy industry, will be exhibiting, presenting, and is ... Summit. The Summit will be held May 4-8, 2015 ... the largest annual gathering for the specialty pharmacy industry. ... providers, pharma/biotech manufacturers, and payers, to learn more about ...
Breaking Biology Technology:NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2
... Laboratories,Inc., a global provider of medical, nutraceutical, consumer ... a letter from The,Nasdaq Stock Market informing the ... of the Company, and would suspend trading in ... business on Thursday, August,16, 2007. As previously ...
... in Number and Viability of Stem Cells Derived from ... BioLife,s Patented Preservation Media, BOTHELL, Wash., Aug. 17 ... developer and marketer of,proprietary hypothermic storage and cryopreservation media ... as the exclusive,supplier of preservation media to the New ...
... Mass., Aug. 17 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... approvable letter from the U.S. Food and Drug ... valrubicin for intravesical,instillation, is the only product approved ... carcinoma in situ (CIS) of the,urinary bladder. ...
Cached Biology Technology:Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets 2BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc. 2BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc. 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... person takes a pill full of a potent and effective drug, ... where it is needed a waste of money and inconvenient ... is a treatment for a serious illness. Polymer chemists ... up to design a solution. Their research to identify, understand, ...
... 2011 Fukushima nuclear plant disaster will reach the shores of ... incident but is likely to be harmless according to new ... atmospheric radiation was detected on the US west coast within ... plume take considerably longer to travel the same distance., In ...
... MD. AUGUST 28, 2013A competition for a $5,000 prize ... member of the American Society for Cell Biology (ASCB) ... The ASCB Kaluza Prize supported by Beckman Coulter, Inc., ... German mathematician Theodor Kaluza (1885-1954), who is the namesake ...
Cached Biology News:Researchers develop novel polymer to help oral medications reach the bloodstream 2Researchers develop novel polymer to help oral medications reach the bloodstream 3Researchers develop novel polymer to help oral medications reach the bloodstream 4Researchers develop novel polymer to help oral medications reach the bloodstream 5Fukushima radioactive plume to reach US in 3 years 2New ASCB Kaluza Prize recognizes graduate student research 2
... Synthesis and Labeling Kit generates labeled cDNA ... unmodified cDNA is made via a reverse ... Oligo(dT) primer. Unlike other methods, there are ... reverse transcription reaction. This unmodified cDNA is ...
The Piezo Power MicroDissection (PPMD) system is designed for rapid isolation of single cells or small cell areas...
... specifically for Alkaline Phosphatase conjugates. The ... for both the enzyme and the antibody ... This product has been chemically engineered to ... longer shelf life, resistance to various shipping ...
AC input: 50-60 Hz230 V...
Biology Products: